Research note
TB-500 and Thymosin Beta-4: Why a Fragment Cannot Stand In for the Whole Protein
TB-500 is a short acetylated fragment, thymosin beta-4 a 43-residue protein, and most published biology concerns the protein. How to tell them apart.
Thymosin beta-4 is an intracellular protein of 43 residues weighing about 4,960 Da. TB-500, as research catalogues sell it, is a short N-acetylated fragment of 889.02 Da. The two share sequence but cannot be swapped for one another, and most of the studies cited for "TB-500" were in fact carried out with the protein. The roughly five-fold gap in molecular weight is also the quickest way to find out which of them a vial really holds.
Comparing the two molecules
The heptapeptide matches the LKKTETQ motif, the part of Tβ4 most closely linked to actin binding. The motif is required for the interaction, but seven residues cannot recreate the binding surface that a 43-residue chain spreads along an actin monomer. Describing the fragment as an actin-sequestering agent at the very least stretches what the smaller molecule can achieve structurally. The concept is defined at fragment.
Which molecule the published biology is really about
The famous thymosin beta-4 results — cardiac findings from a prominent 2004 paper, corneal and skin wound-healing models, hair follicle research, endothelial migration assays — were obtained with full-length Tβ4, mostly recombinant. The clinical development programmes that progressed to human trials, among them ophthalmic and dermal formulations, also used the complete protein. It is a sizeable and valid body of work, and none of it studies the heptapeptide.
The fragment does have a literature of its own, mostly concerned with how the motif contributes to cell migration and angiogenic signalling in vitro. It is something, but it is a separate and far slimmer evidence base. Whenever a summary cites "TB-500 research" and then describes cardiac or corneal results, it has quietly swapped one molecule for the other.
For study design the consequence is plain: when your hypothesis rests on the biology of full-length Tβ4, the fragment is not the right reagent to test it. Structural background is in what is TB-500.
Why beta-thymosins resist being cut down
The fragment cannot substitute for the protein for structural, not merely semantic, reasons. In free solution beta-thymosins are intrinsically disordered, taking up an extended shape only when they bind actin, at which point an N-terminal helix, a central section containing the LKKTETQ motif and a C-terminal segment lie across different faces of the monomer. The binding energy is spread over that entire length. Cut out seven residues and you keep a recognition element but lose the framework that positions it — which is why isolated motif peptides in the beta-thymosin literature interact much more weakly than the parent protein.
This is a general rule about peptide fragments, not a peculiarity of this one. A fragment copies a sequence, not necessarily a function, and anyone who claims otherwise carries the burden of proof. The same care is needed throughout the catalogue whenever a short peptide bears the name of a larger parent — the fragment should earn its own literature before it borrows the parent’s.
A naming problem in research supply
"TB-500" is a trade name in catalogues, not a chemical identity, and different suppliers have used it for both molecules. Some offer the heptapeptide; others sell full-length Tβ4 under the same name. Neither is wrong as such, but a protocol that fails to state which one was used cannot be reproduced.
A single glance at the certificate of analysis settles the matter. A mass spectrum with a species near 889 Da — or a doubly charged ion close to 445 — indicates the heptapeptide. A spectrum around 4,960 Da, usually appearing as a charge-state envelope spread over several m/z values, indicates the full protein. These two values cannot be confused. The method for reading it is in mass spectrometry and peptide identity, with the general reading guide in how to read a peptide COA and the unit itself at molecular weight (Da).
The acetyl group at the N-terminus deserves a mention as well. In cells, native Tβ4 is acetylated at its N-terminus, and the research heptapeptide carries the same modification — hence its presence in the catalogue name and the observed mass sitting 42 Da above that of the free-amine sequence. Defined at acetylation.
Handling the fragment in practice
At 889.02 Da the heptapeptide is small, very polar and dissolves easily in water — simpler to work with than most of the catalogue. Assessing risk from its sequence is quick: it has no methionine, cysteine or tryptophan, so oxidation, disulfide scrambling and light-induced breakdown are all minor concerns. The threonine and glutamine residues are the ones to consider during long storage in solution.
The molar maths is easy: a 5 mg vial equals about 5.62 µmol of peptide before correcting for net content, far more moles than the same mass of a 4–5 kDa peptide. When comparing a fragment with a full-length protein in any assay, it is essential to work in molar rather than mass units — 5 mg of the heptapeptide contains about five and a half times as many moles as 5 mg of Tβ4.
TB-500 research vials come in 5, 10 and 20 mg, with an oral research product in TB-500 capsules and a fixed-ratio pairing in the BPC-157 + TB-500 blend. The head-to-head with the other widely studied repair peptide is in BPC-157 vs TB-500, and the category sits in tissue repair peptides.
How to describe it in a methods section
Identify the molecule by its sequence and mass, not by a catalogue nickname. "Ac-LKKTETQ, observed [M+H]+ 890.0, lot XXXX" leaves no doubt; "TB-500" does. If your work relies on the biology of full-length thymosin beta-4, obtain and report the full-length protein. If it concerns the motif specifically, report the fragment. Making the distinction takes a single line and avoids a whole category of later misinterpretation.
Questions
Are TB-500 and thymosin beta-4 the same thing?
No. Thymosin beta-4 is a protein of 43 residues and about 4,960 Da. TB-500 as usually sold is an acetylated seven-residue fragment of 889.02 Da that corresponds to the region of the actin-binding motif. They share part of their sequence but differ roughly five-fold in mass, and equivalent behaviour cannot be assumed.
How do I find out which molecule a vial contains?
Look at the mass spectrum on the certificate of analysis. A species close to 889 Da, or a doubly charged ion near 445, points to the heptapeptide. A neutral mass around 4,960 Da, normally visible as an envelope of multiply charged ions, points to full-length thymosin beta-4. The values are so far apart that confusion is impossible.
Does the fragment bind and sequester actin like the full protein?
Its structure gives no reason to expect so. Thymosin beta-4 sequesters actin through an extended contact running along the actin monomer, which a peptide of seven residues cannot replicate even though the LKKTETQ motif sits at the heart of that contact. Calling the fragment an actin-sequestering agent claims more than its size allows.
Which molecule did the famous cardiac and corneal studies use?
Full-length thymosin beta-4, mostly produced recombinantly. Those studies, and the later clinical development programmes for eye and skin indications, used the complete protein. Crediting that work to the heptapeptide is a frequent mistake in secondary summaries.
Why is TB-500 acetylated at the N-terminus?
In cells, native thymosin beta-4 carries an N-terminal acetyl group, and the research fragment copies that modification. It adds 42 Da compared with the free-amine sequence, explaining the observed mass of 889.02 Da and why the catalogue name is written Ac-LKKTETQ.
Should the fragment and the protein be compared by mass or in molar units?
Always in molar units. The same mass of each corresponds to very different numbers of moles — about a five-and-a-half-fold difference — so comparing by mass distorts how many molecules are present and renders the results impossible to interpret.